2023
Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis
Karunarathne W, Lee K, Choi Y, Kang C, Lee M, Kim S, Kim G. Investigating rutin as a potential transforming growth factor‐β type I receptor antagonist for the inhibition of bleomycin‐induced lung fibrosis. BioFactors 2023, 50: 477-492. PMID: 38006284, DOI: 10.1002/biof.2020.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisEpithelial-mesenchymal transitionPotential of rutinLung fibrosisType I receptor antagonistChronic lung conditionsPotential therapeutic optionTGF-β type I receptorFibrotic signaling pathwaysInhibition of bleomycinSmooth muscle actinNon-toxic concentrationsType I receptorPulmonary fibrosisCancer-related diseasesTherapeutic optionsReceptor antagonistLung conditionsLung fibroblast cellsFibrosisMuscle actinEMT processType 1ECM-related genesTGF
2020
Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis
Kim SH, Lee JY, Yoon CM, Shin HJ, Lee SW, Rosas I, Herzog E, Dela Cruz C, Kaminski N, Kang MJ. Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis. European Respiratory Journal 2020, 57: 2000652. PMID: 33093124, PMCID: PMC8559259, DOI: 10.1183/13993003.00652-2020.Peer-Reviewed Original ResearchConceptsDamage-associated molecular patternsIdiopathic pulmonary fibrosisPulmonary fibrosisMAVS aggregationMultiple damage-associated molecular patternsExperimental pulmonary fibrosisMitochondrial antiviral signaling proteinInnate immune responseIPF patientsMAVS signalingIPF treatmentBleomycin injuryLung fibrosisTherapeutic effectImmune responseTherapeutic strategiesMAVS expressionFibrosisDanger signalsCritical mediatorMolecular patternsABT-263LungInjuryBH3 mimetics